<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151527</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00022485</org_study_id>
    <secondary_id>R01HL097163-01</secondary_id>
    <secondary_id>RC1HL099571</secondary_id>
    <nct_id>NCT01151527</nct_id>
  </id_info>
  <brief_title>Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias</brief_title>
  <official_title>Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that a peripheral blood biomarker or biological signature (gene or protein&#xD;
      expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve&#xD;
      the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable,&#xD;
      stage of their disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Broad Challenge Area addressed in this proposal is (03) Biomarker Discovery and&#xD;
      Validation, and the Specific Challenge Topic is 03-HL-101 (Identify and validate clinically&#xD;
      relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood,&#xD;
      vascular, cardiac, and respiratory tract dysfunction). Idiopathic interstitial pneumonia&#xD;
      (IIP) is a lung disease(s) that primarily affects the elderly, but is present in all age&#xD;
      groups. IIP causes respiratory insufficiency and is often fatal. In about half of the&#xD;
      patients, the diagnosis requires an invasive lung biopsy which can cause complications, and&#xD;
      is not always accurate.&#xD;
&#xD;
      The current diagnostic tools for IIP are inadequate. In addition to inaccurate diagnosis,&#xD;
      they are very costly, and often result in delayed diagnosis and treatment. The challenge(s)&#xD;
      we intend to address in this proposal is to improve the accurate and early diagnosis of&#xD;
      idiopathic interstitial lung pneumonia (IIP), and to improve the ability to differentiate the&#xD;
      subtypes of idiopathic interstitial pneumonias (IIPs) by developing peripheral blood&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">269</enrollment>
  <condition>Idiopathic Interstitial Pneumonias</condition>
  <arm_group>
    <arm_group_label>Sporadic (idiopathic) or familial interstitial pneumonia</arm_group_label>
    <description>We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tubes of blood will be drawn from the subject to extract RNA and DNA for laboratory purposes.&#xD;
&#xD;
      Lung biopsy tissue (pathology slides) may be requested for specimen processing.&#xD;
&#xD;
      Also Bronchoscopy fluid may be requested.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic&#xD;
        Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals&#xD;
        in a family).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sporadic cases of Idiopathic Pulmonary Fibrosis and other types of Idiopathic&#xD;
             Interstitial Pneumonias.&#xD;
&#xD;
          -  Family members ( with or without clinical disease) with a family history of pulmonary&#xD;
             fibrosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark P Steele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Hamman-Rich Syndrome</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

